Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Duke, FDA partner on clinical trial modernization

This article was originally published in The Gray Sheet

Executive Summary

FDA and Duke University Medical Center are teaming up to modernize the way clinical trials are conducted, spearheading a public-private partnership of government, industry, health care and academic stakeholders, the organizations say. An executive and steering committee will develop new standards and identify ways to improve safety, quality of information and the research process. Key initiatives include setting national standards for things like electronic data forms and contractual agreements to streamline a "too slow and unnecessarily complicated" process, and creating accreditation programs for clinical investigators and research sites. Duke's Robert M. Califf, MD, and FDA's Rachel Behrman, director of the agency's office of critical path programs, will co-chair the partnership

Latest Headlines
See All
UsernamePublicRestriction

Register

MT025546

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel